ArticleTherapeutic advances in gastroenterology2025
Thromboembolic and cardiovascular risk profiles in patients with ulcerative colitis initiating advanced therapies.
Article in Therapeutic advances in gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ulcerative colitis (UC) is associated with an increased risk of venous thromboembolism (VTE) and cardiovascular (CV) events, particularly during flares. While concerns have emerged regarding the intrinsic CV and thromboembolic risk of Janus kinase inhibitors, real-world data on baseline risk profiles in UC remain scarce. Objectives: This study aimed to assess the thromboembolic and cardiovascular risk profiles of UC outpatients initiating advanced therapies and to evaluate the incidence of related clinical events. Design: We conducted a cross-sectional study with prospective longitudinal follow-up at a single tertiary center. Methods: Consecutive UC outpatients who initiated an advanced therapy between June 2020 and December 2023 were enrolled. Baseline VTE and CV risk factors were assessed using medical records, a structured online questionnaire, and the International Physical Activity Questionnaire. CV risk was estimated using the Atherosclerotic Cardiovascular Disease and Systematic Coronary Risk Estimation 2 calculators. Patients were monitored for VTE and CV events until December 2024. Results: The study included 300 patients (median age 44 years; 45.3% female). Most had 0-1 VTE risk factor (61.0%) and elevated C-reactive protein was the most common (45.0%). CV risk stratification showed that most non-elderly patients had low or moderate risk, while elderly patients showed higher risk. During a median follow-up of 27 months (683 person-years), only four events (1.3%, incidence rate 0.59 per 100 P-Y) were recorded: two VTE (both in patients on ustekinumab, one with multiple risk factors and one with cirrhosis) and two CV events (angina and retinal ischemia in low-risk patients on vedolizumab and adalimumab). Conclusion: In our cohort, both thromboembolic and CV risks were overall low. CV risk was higher in elderly patients. The incidence of VTE and CV events during follow-up was low. These findings suggest that concerns regarding the intrinsic VTE and CV risks associated with Janus kinase inhibitors may not fully apply to UC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.